Johnson & Johnson On Track For Eight NME Filings, Approvals In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans to submit a follow-on to the recently approved antipsychotic Invega by year-end.
You may also be interested in...
Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition
Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.
Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition
Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.
J&J Seeks Approval For Doxil Plus Velcade In Multiple Myeloma
Supplemental claim for liposomal doxorubicin has a May 21 priority review date, J&J’s Ortho Biotech unit tells “The Pink Sheet” DAILY.